. Author manuscript; available in PMC: 2016 Mar 4.

Published in final edited form as: J Natl Compr Canc Netw. 2015 Oct;13(10):1225–1231. doi: 10.6004/jnccn.2015.0151

Table 2.

Severity and Frequency of Posttreatment Lymphopenia

	Pooled Data	Malignant Glioma	Resected Pancreatic Cancer	Unresectable Pancreatic Cancer	Stage III NSCLC
Baseline TLC, median (range)	1484 (331–5,030)	1418 (331–4,736)	1945 (580–4,200)	1455 (426–5,030)	1510 (570–3,336)
TLC 2 months after starting radiation, median (range)	560 (0–4,074)	635 (49–1,683)	610 (0–4,074)	560 (100–2,960)	500 (131–2,040)
TLC reduction at 2 months	63%	58%	67%	63%	61%
Patients at 2 months with grade III/IV TRL	43%	37%	45%	46%	49%

Abbreviations: NSCLC, non–small cell lung cancer; TLC, total lymphocyte count; TRL, treatment-related lymphopenia.